2 results ยท Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
A Phase 1/2 Study of the Safety and Efficacy of BRX011 Oral Administration Once Daily in Subjects With Geographic Atrophy Secondary to Age-Related Macular DegenerationGeographic Atrophy, eye disorder, macular degeneration, retinal degeneration, retinal disorderRecruitingPhase 1 / Phase 22026-09-23NCT07029945
A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)diabetic macular edemaActive, not recruitingPhase 32026-09-18NCT06491914